On the other hand, a significant proportion of CRC patients with the wild-type (normal) KRAS gene fail to respond to EGFR inhibitors and mutations in other genes such as PIK3CA/BRAF/NRAS/PTEN/TP53 have been implicated for resistance in this subgroup of patients[7-9]. This evidence concerns the gene BRAF and colorectal carcinoma.